Cohance Lifesciences Ltd: 109× P/E – Science, Contracts & a Touch of Financial Gymnastics
1. At a Glance
Cohance is riding the CDMO wave harder than a biotech bro at an FDA approval party. It just posted 13% YoY revenue growth in Q1 FY26, expanded margins, and announced new facility investments — but also dropped a YoY PAT decline thanks to cost creep and a less-than-stellar quarter in profits. With a P/E of 109, the market is clearly convinced it’s the next Divi’s Labs… or it’s had too much pharma Kool-Aid.
2. Introduction
In pharma land, being a Contract Development & Manufacturing Organisation (CDMO) is like being the backstage crew of a rock concert — you don’t sing, but without you, the show can’t go on. Cohance plays in that space, helping global innovators with everything from early-stage R&D to commercial manufacturing.
It’s one of the top 5 providers of high-end intermediates in India, which sounds glamorous until you realise 100% of promoter holding is pledged — meaning the backstage crew might also have a small loan problem.
3. Business Model (WTF Do They Even Do?)
Cohance operates in the CRAMS space (Contract Research & Manufacturing Services), focused on:
NCE Development – process R&D for new chemical entities.
Late-stage & commercial manufacturing – scaling up from lab batches to industrial scale.
Speciality Intermediates – high-value intermediates for innovators.
Oligonucleotide Manufacturing – shiny new ₹230 mn cGMP facility in Hyderabad for advanced therapeutics.
Customers? Global pharma majors and fine chemical leaders. It’s high-margin, high-barrier work, but also high-dependence on a few large clients.
